AstraZeneca PLC

AZN

GB0009895292

Pharmaceuticals

Market Closed - London S.E. Other stock markets 11:35:29 2024-09-18 am EDT			5-day change	1st Jan Change
11,856.00 ^GBX	-0.94%		-3.67%	+11.85%

01:43pm	AstraZeneca Says US FDA Approves Fasenra for Rare Vasculitis Treatment	MT
01:04pm	Glum trade for FTSE 100 before Fed decides	AN

ASTRAZENECA : Deutsche Bank remains Neutral

July 29, 2024 at 06:01 am EDT

In a research note, Deutsche Bank analyst Emmanuel Papadakis has maintained his recommendation on the stock with a Neutral rating. The target price is unchanged and still at GBX 11000.

Latest news about AstraZeneca PLC

AstraZeneca Says US FDA Approves Fasenra for Rare Vasculitis Treatment	07:43am	MT
Glum trade for FTSE 100 before Fed decides	07:04am	AN
ASTRAZENECA : Goldman Sachs maintains a Buy rating	05:12am	ZD
AstraZeneca: new US approval for Fasenra	05:04am	CF
AstraZeneca Fasenra treatment for EGPA approved in the US	04:40am	AN
Legal & General sells CALA arm for GBP1.35 billion	02:50am	AN
US FDA Approves AstraZeneca's Fasenra to Treat Rare, Immune-mediated Vasculitis EGPA	02:21am	MT
AstraZeneca PLC's Fasenra Approves in the US for Eosinophilic Granulomatosis with Polyangiitis	02:00am	CI
REGENXBIO Inc. Announces Chief Financial Officer Changes	Sep. 17	CI
REGENXBIO Inc. Announces Executive Changes	Sep. 17	CI
ASTRAZENECA : JP Morgan keeps its Buy rating	Sep. 17	ZD
Sanofi, AstraZeneca Win US Approval for New RSV Vaccine Manufacturing Line	Sep. 16	MT
European Equities Close Mostly Lower in Monday Trading; Deutsche Bank Aims to Block UniCredit From Buying Commerzbank Stake	Sep. 16	MT
Sanofi Shipping Beyfortus in US Ahead of Respiratory Syncytial Virus Disease Season	Sep. 16	MT
Exchange-Traded Funds Lower, Equity Futures Mixed Pre-Bell as Investors Mull Possible Rate Cut	Sep. 16	MT
AstraZeneca Says Hepatocellular Carcinoma Combination Therapy Trial Showed 'Sustained, Clinically Meaningful Overall Survival Benefit' at 5 Years	Sep. 16	MT
AstraZeneca: several positive results in cancer	Sep. 16	CF
AstraZeneca celebrates survival rate of Imfinzi-Imjudo mix	Sep. 16	AN
AstraZeneca's Trial Shows IMFINZI Reduces Risk of Recurrence, Death in Patients With Bladder Cancer	Sep. 16	MT
AstraZeneca's Imfinzi Combination Shows Sustained Survival Rate at Five-year Follow-up	Sep. 16	MT
ASTRAZENECA : UBS reiterates its Sell rating	Sep. 16	ZD
AstraZeneca Reports Positive Results from Trial of Imfinzi in Muscle-invasive Bladder Cancer	Sep. 16	MT
AstraZeneca Announces Positive Results from the Niagara Phase III Trial	Sep. 15	CI
SOPHiA GENETICS Presents Multimodal Research on AI-Driven Patient Stratification at ESMO 2024	Sep. 14	CI
AstraZeneca, Daiichi Sankyo Breast Cancer Drug Trial Shows 'Substantial Clinical Activity'	Sep. 13	MT

AstraZeneca PLC is one of the world's leading pharmaceutical groups. Net sales break down by source of income as follows: - product sales (95.6%). Net sales break down by treatment area between oncology (39.2%), cardiovascular, renal and metabolic diseases (24.2%), respiratory and autoimmune diseases (13.9%), and other (22.7%; inflammatory diseases, neurological diseases, gastrointestinal and infectious diseases); - collaboration revenue (4.4%). Net sales are distributed geographically as follows: the United Kingdom (7.4%), Europe (21.2%), America (45.3%) and Africa-Asia-Australia (26.1%).

Employees

89,900

Sector

Pharmaceuticals

Calendar

2024-09-17 - Bank of America Global Healthcare Conference

More about the company